247 related articles for article (PubMed ID: 22810490)
1. Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes.
van Doorn R; Nijland PG; Dekker N; Witte ME; Lopes-Pinheiro MA; van het Hof B; Kooij G; Reijerkerk A; Dijkstra C; van van der Valk P; van Horssen J; de Vries HE
Acta Neuropathol; 2012 Sep; 124(3):397-410. PubMed ID: 22810490
[TBL] [Abstract][Full Text] [Related]
2. Fingolimod prevents blood-brain barrier disruption induced by the sera from patients with multiple sclerosis.
Nishihara H; Shimizu F; Sano Y; Takeshita Y; Maeda T; Abe M; Koga M; Kanda T
PLoS One; 2015; 10(3):e0121488. PubMed ID: 25774903
[TBL] [Abstract][Full Text] [Related]
3. Sphingosine 1-phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions.
Van Doorn R; Van Horssen J; Verzijl D; Witte M; Ronken E; Van Het Hof B; Lakeman K; Dijkstra CD; Van Der Valk P; Reijerkerk A; Alewijnse AE; Peters SL; De Vries HE
Glia; 2010 Sep; 58(12):1465-76. PubMed ID: 20648639
[TBL] [Abstract][Full Text] [Related]
4. Targeting intracerebral inflammation in multiple sclerosis: is it feasible?
Lassmann H
Acta Neuropathol; 2012 Sep; 124(3):395-6. PubMed ID: 22797580
[No Abstract] [Full Text] [Related]
5. Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide.
Colombo E; Di Dario M; Capitolo E; Chaabane L; Newcombe J; Martino G; Farina C
Ann Neurol; 2014 Sep; 76(3):325-37. PubMed ID: 25043204
[TBL] [Abstract][Full Text] [Related]
6. Astrocyte-derived retinoic acid: a novel regulator of blood-brain barrier function in multiple sclerosis.
Mizee MR; Nijland PG; van der Pol SM; Drexhage JA; van Het Hof B; Mebius R; van der Valk P; van Horssen J; Reijerkerk A; de Vries HE
Acta Neuropathol; 2014 Nov; 128(5):691-703. PubMed ID: 25149081
[TBL] [Abstract][Full Text] [Related]
7. [Fingolimod therapy in multiple sclerosis--the issue of the pathomechanism].
Tar L; Vécsei L
Ideggyogy Sz; 2012 Mar; 65(3-4):83-100. PubMed ID: 23136726
[TBL] [Abstract][Full Text] [Related]
8. Sphingosine 1 Phosphate at the Blood Brain Barrier: Can the Modulation of S1P Receptor 1 Influence the Response of Endothelial Cells and Astrocytes to Inflammatory Stimuli?
Spampinato SF; Obermeier B; Cotleur A; Love A; Takeshita Y; Sano Y; Kanda T; Ransohoff RM
PLoS One; 2015; 10(7):e0133392. PubMed ID: 26197437
[TBL] [Abstract][Full Text] [Related]
9. Sphingosine 1-phosphate signaling at the blood-brain barrier.
Prager B; Spampinato SF; Ransohoff RM
Trends Mol Med; 2015 Jun; 21(6):354-63. PubMed ID: 25939882
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS.
Kowarik MC; Pellkofer HL; Cepok S; Korn T; Kümpfel T; Buck D; Hohlfeld R; Berthele A; Hemmer B
Neurology; 2011 Apr; 76(14):1214-21. PubMed ID: 21464424
[TBL] [Abstract][Full Text] [Related]
11. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis.
Dev KK; Mullershausen F; Mattes H; Kuhn RR; Bilbe G; Hoyer D; Mir A
Pharmacol Ther; 2008 Jan; 117(1):77-93. PubMed ID: 17961662
[TBL] [Abstract][Full Text] [Related]
12. [Basic mechanisms of action of fingolimod in relation to multiple sclerosis].
García-Merino JA; Sánchez AJ
Rev Neurol; 2012 Jul; 55(1):31-7. PubMed ID: 22718407
[TBL] [Abstract][Full Text] [Related]
13. IFN-beta regulates CD73 and adenosine expression at the blood-brain barrier.
Niemelä J; Ifergan I; Yegutkin GG; Jalkanen S; Prat A; Airas L
Eur J Immunol; 2008 Oct; 38(10):2718-26. PubMed ID: 18825744
[TBL] [Abstract][Full Text] [Related]
14. Distinct properties of circulating CD8+ T cells in FTY720-treated patients with multiple sclerosis.
Johnson TA; Lapierre Y; Bar-Or A; Antel JP
Arch Neurol; 2010 Dec; 67(12):1449-55. PubMed ID: 21149809
[TBL] [Abstract][Full Text] [Related]
15. Cellular distribution of glucose and monocarboxylate transporters in human brain white matter and multiple sclerosis lesions.
Nijland PG; Michailidou I; Witte ME; Mizee MR; van der Pol SM; van Het Hof B; Reijerkerk A; Pellerin L; van der Valk P; de Vries HE; van Horssen J
Glia; 2014 Jul; 62(7):1125-41. PubMed ID: 24692237
[TBL] [Abstract][Full Text] [Related]
16. Investigation of immune and CNS-mediated effects of fingolimod in the focal delayed-type hypersensitivity multiple sclerosis model.
Anthony DC; Sibson NR; Losey P; Meier DP; Leppert D
Neuropharmacology; 2014 Apr; 79():534-41. PubMed ID: 24412675
[TBL] [Abstract][Full Text] [Related]
17. Central nervous system-directed effects of FTY720 (fingolimod).
Miron VE; Schubart A; Antel JP
J Neurol Sci; 2008 Nov; 274(1-2):13-7. PubMed ID: 18678377
[TBL] [Abstract][Full Text] [Related]
18. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis.
Mehling M; Johnson TA; Antel J; Kappos L; Bar-Or A
Neurology; 2011 Feb; 76(8 Suppl 3):S20-7. PubMed ID: 21339487
[TBL] [Abstract][Full Text] [Related]
19. Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite.
Strader CR; Pearce CJ; Oberlies NH
J Nat Prod; 2011 Apr; 74(4):900-7. PubMed ID: 21456524
[TBL] [Abstract][Full Text] [Related]
20. Suppressed pro-inflammatory properties of circulating B cells in patients with multiple sclerosis treated with fingolimod, based on altered proportions of B-cell subpopulations.
Miyazaki Y; Niino M; Fukazawa T; Takahashi E; Nonaka T; Amino I; Tashiro J; Minami N; Fujiki N; Doi S; Kikuchi S
Clin Immunol; 2014 Apr; 151(2):127-35. PubMed ID: 24607506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
